Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Stage IV Ovarian Cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    206 result(s) found for: Stage IV Ovarian Cancer. Displaying page 1 of 11.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-004484-54 Sponsor Protocol Number: IP-CAT-OC-02 Start Date*: 2007-08-30
    Sponsor Name:Fresenius Biotech GmbH
    Full Title: Multicenter, single-arm, phase II study of the tri functional antibody catumaxomab (anti EpCAM x anti-CD3) administered intra- and postoperatively in patients with epithelial ovarian cancer
    Medical condition: Epithelial Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033162 Ovarian epithelial cancer stage II LLT
    9.1 10033163 Ovarian epithelial cancer stage III LLT
    9.1 10033164 Ovarian epithelial cancer stage IV LLT
    9.1 10033161 Ovarian epithelial cancer stage I LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001506-25 Sponsor Protocol Number: NN028-1802 Start Date*: Information not available in EudraCT
    Sponsor Name:Novo Nordisk A/S
    Full Title: An open–label Phase 2 Trial of Pegylated Liposomal Doxorubicin and rIL-21 in Ovarian Cancer Patients with Persistent or Progressive Disease after, or Relapse within One Year of, Completion of Stand...
    Medical condition: advanced epithelial Ovarian Cancer stage IIB-IV
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033162 Ovarian epithelial cancer stage II LLT
    9.1 10033163 Ovarian epithelial cancer stage III LLT
    9.1 10033164 Ovarian epithelial cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-002014-22 Sponsor Protocol Number: ONK-MAP/AZD2281-01 Start Date*: 2014-05-27
    Sponsor Name:Országos Onkológiai Intézet
    Full Title: An open label, single center, non-randomised, phase II study of efficacy Olaparib in patients with BRCA mutation posistive previously treated advanced ocarium cancer
    Medical condition: advanced ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-023457-11 Sponsor Protocol Number: S52798 Start Date*: 2011-02-15
    Sponsor Name:UZ Leuven
    Full Title: Immune regulation and timing of chemotherapy in advanced/recurrent ovarian and endometrial cancer
    Medical condition: advanced/recurrent ovarian and endometrial cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10057529 Ovarian cancer metastatic LLT
    12.1 10066697 Ovarian cancer recurrent LLT
    12.1 10057529 Ovarian cancer metastatic PT
    12.1 10066697 Ovarian cancer recurrent PT
    12.1 10014734 Endometrial cancer metastatic LLT
    12.1 10014736 Endometrial cancer recurrent LLT
    12.1 10014734 Endometrial cancer metastatic PT
    12.1 10014736 Endometrial cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001661-32 Sponsor Protocol Number: VeTo Start Date*: 2012-07-05
    Sponsor Name:Vejle Hospital, Dept. of Oncology
    Full Title: Veliparib (ABT888) and Topotecan (Hycamtin®) for Patients with Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer with Negative or Unknown BRCA Status
    Medical condition: Relapsed epithelial, platinum resistant ovarian cancer with negative or unknown BRCA status
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-004429-41 Sponsor Protocol Number: BAY43-9006/12007 Start Date*: 2008-10-03
    Sponsor Name:Bayer Healthcare AG
    Full Title: A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients who have achieved a ...
    Medical condition: The study population will include patients with FIGO stage III or IV ovarian cancer or primary peritoneal cancer who have had extensive debulkment surgery and who have achieved a clinical complete ...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052171 Peritoneal carcinoma LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033164 Ovarian epithelial cancer stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033163 Ovarian epithelial cancer stage III PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) NL (Completed) IT (Completed) ES (Completed) FR (Completed) FI (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-023613-61 Sponsor Protocol Number: IPR/24 Start Date*: 2011-06-13
    Sponsor Name:MOLMED
    Full Title: NGR018: Randomized phase II study of NGR-hTNF plus pegylated liposomal doxorubicin (PLD) versus PLD in platinum-resistant ovarian cancer
    Medical condition: Advanced or metastatic platinum-resistant ovarian cancer patients
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-011041-12 Sponsor Protocol Number: ET-A-018-09 Start Date*: 2009-07-23
    Sponsor Name:Pharma Mar S.A.
    Full Title: Étude multicentrique de phase Ib-II en escalade de dose de la trabectédine (Yondelis®) en association avec l’oxaliplatine chez des patientes atteintes d’un cancer de l’ovaire avancé prétraité.
    Medical condition: Pretreated Advanced Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057529 Ovarian cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004644-24 Sponsor Protocol Number: sorOVAR_07 Start Date*: 2007-05-23
    Sponsor Name:University of Bonn
    Full Title: Prospective, open label, multi center phase II clinical trial with neoadjuvant chemotherapy in addition with Sorafenib in patients with primarily advanced ovarian cancer (FIGO IIIC + IV) and asci...
    Medical condition: Ovarian Cancer; Stage FIGO IIIc and IV with more than 500 ml ascites
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057529 Ovarian cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002663-26 Sponsor Protocol Number: AEZS-108-040 Start Date*: 2007-12-05
    Sponsor Name:AEterna Zentaris GmbH
    Full Title: Antitumoral activity and safety of AEZS-108 (AN-152), a LHRH agonist linked doxorubicin, in women with LHRH receptor positive gynecological tumors
    Medical condition: Histologically confirmed malignancy of ovary or endometrium that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective and LHR...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007069 Cancer of endometrium stage III LLT
    9.1 10007065 Cancer of endometrium recurrent LLT
    9.1 10007070 Cancer of endometrium stage IV LLT
    9.1 10057529 Ovarian cancer metastatic LLT
    9.1 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2004-001457-28 Sponsor Protocol Number: CAM203 Start Date*: 2004-09-09
    Sponsor Name:CELL THERAPEUTICS EUROPE
    Full Title: Phase II open label study of CT-2106 as a single agent in patients with advanced metastatic ovarian cancer who have failed one prior platinum and taxane based regimen
    Medical condition: Treatment of patients with advanced ovarian cancer who have failed one prior platinum and taxane based regimen
    Disease: Version SOC Term Classification Code Term Level
    6.1 10057529 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000004-33 Sponsor Protocol Number: IPR/18 Start Date*: 2008-10-13
    Sponsor Name:MOLMED
    Full Title: NGR012: A phase II study of NGR-hTNF administered in combination with doxorubicin every 3 weeks in patients affected by advanced or metastatic ovarian cancer
    Medical condition: Patients affected by advanced or metastatic ovarian cancer previously treated with platinum regimens (cis or carboplatin) plus paclitaxel
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-005091-36 Sponsor Protocol Number: 2020-005091-36 Start Date*: 2021-08-30
    Sponsor Name:Stichting Catharina Hospital
    Full Title: Signal TrAnsduction Pathway activity analysis for OVarian cancER treatment. STAPOVER study
    Medical condition: Ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033131 Ovarian carcinoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070905 Ovarian cancer stage I PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070906 Ovarian cancer stage II PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070907 Ovarian cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070908 Ovarian cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007107 Cancer of ovary LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026310 Malignant neoplasm of ovary LLT
    Population Age: Elderly Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-003772-35 Sponsor Protocol Number: AURA-6202-006 Start Date*: 2007-09-09
    Sponsor Name:Nerviano Medical Sciences S.r.l.
    Full Title: Phase II study of PHA-739358 administered by a 24-hour IV infusion every 14 days in advanced/metastatic breast, ovarian, colorectal, pancreatic, small cell lung and non small cell lung cancers.
    Medical condition: Advanced/metastatic breast, ovarian, colorectal, pancreatic, small cell lung, non small cell lung and squamous non small cell lung cancers.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059514 Small cell lung cancer metastatic PT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033610 Pancreatic carcinoma metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) IT (Completed) FR (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-005504-13 Sponsor Protocol Number: 2006.444/37 Start Date*: 2007-03-15
    Sponsor Name:HOSPICES CIVILS DE LYON
    Full Title: ETUDE MULTICENTRIQUE FAG-3 : TRAITEMENT PAR CARBOPLATINE DES PATIENTES DE PLUS DE 70 ANS ATTEINTES DE CANCER AVANCE DE L’OVAIRE : PREDICTION DE LA VULNERABILITE INDIVIDUELLE PAR UNE EVALUATION PSY...
    Medical condition: cancer avancé de l'ovaire
    Disease: Version SOC Term Classification Code Term Level
    8.1 10057529 Ovarian cancer metastatic LLT
    Population Age: Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005576-26 Sponsor Protocol Number: 08-PIR-04 Start Date*: 2009-02-19
    Sponsor Name:Nektar Therapeutics
    Full Title: A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) When Given on a Q14 Day or a Q21 Day Schedule in Patients with Metastatic or Unresectable L...
    Medical condition: Metastatic or Unresectable Locally Advanced Platinum-Resistant Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-001982-34 Sponsor Protocol Number: MOVES Start Date*: 2022-04-19
    Sponsor Name:Pirkanmaan hyvinvointialue
    Full Title: Measuring Oncogical Value of Exercise and Statin
    Medical condition: Metastatic breast, ovarian, kidney and prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023400 Kidney cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023404 Kidney cancer stage III LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023405 Kidney cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004850-14 Sponsor Protocol Number: GEICO-1601 Start Date*: 2017-11-13
    Sponsor Name:Grupo Español de Investigación en Cancer de Ovario
    Full Title: Multicentric Single Arm Phase II Clinical Trial, to Evaluate Safety and Efficacy of the Combination of Olaparib and PLD for Platinum Resistant Ovarian Primary Peritoneal Carcinoma, and Fallopian Tu...
    Medical condition: Platinum resistant ovarian primary peritoneal carcinoma, and fallopian tube cancer patients.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070908 Ovarian cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-000126-31 Sponsor Protocol Number: 1401 Start Date*: 2006-06-24
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: A phase II trial of carboplatin and paclitaxel compared with carboplatin or gemcitabine paclitaxel "induction" followed by carboplatin/paclitaxel/gemcitabine in patients with suboptimally resected ...
    Medical condition: Epithelial ovarian carcinoma
    Disease: Version SOC Term Classification Code Term Level
    6.1 10033163 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003492-29 Sponsor Protocol Number: 391402 Start Date*: 2016-03-02
    Sponsor Name:Baxalta Innovations GmbH
    Full Title: A Phase 1/2a, Open-Label, Parallel, Two-Arm, Dose-Escalation Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BAX69 in Subjects with Refractory Ovarian...
    Medical condition: Refractory Ovarian Cancer with Malignant Ascites
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 17 07:18:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA